Medical Molecular Genetics, Human Genetics and Genome Research Institute, National Research Centre, Cairo, Egypt.
Clinical Genetics Department, Human Genetics and Genome Research Institute, National Research Centre, Cairo, 12311, Egypt.
J Mol Neurosci. 2024 Oct 5;74(4):93. doi: 10.1007/s12031-024-02266-8.
Collagen VI-related dystrophies (COL6-RD) display a wide spectrum of disease severity and genetic variability ranging from mild Bethlem myopathy (BM) to severe Ullrich congenital muscular dystrophy (UCMD) and the intermediate severities in between with dual modes of inheritance, dominant and recessive. In the current study, next-generation sequencing demonstrated potential variants in the genes coding for the three alpha chains of collagen VI (COL6A1, COL6A2, or COL6A3) in a cohort of Egyptian patients with progressive muscle weakness (n = 23). Based on the age of disease onset and the patient clinical course, subjects were diagnosed as follows: 12 with UCMD, 8 with BM, and 3 with intermediate disease form. Fourteen pathogenic variants, including 5 novel alterations, were reported in the enrolled subjects. They included 3 missense, 3 frameshift, and 6 splicing variants in 4, 3, and 6 families, respectively. In addition, a nonsense variant in a single family and an inframe variant in 3 different families were also detected. Recessive and dominant modes of inheritance were recorded in 9 and 8 families, respectively. According to ACMG guidelines, variants were classified as pathogenic (n = 7), likely pathogenic (n = 4), or VUS (n = 3) with significant pathogenic potential. To our knowledge, the study provided the first report of the clinical and genetic findings of a cohort of Egyptian patients with collagen VI deficiency. Inter- and intra-familial clinical variability was evident among the study cohort.
胶原 VI 相关营养不良症(COL6-RD)表现出广泛的疾病严重程度和遗传变异性,从轻度 Bethlem 肌病(BM)到严重 Ullrich 先天性肌营养不良症(UCMD)以及中间严重程度,遗传方式为显性和隐性。在本研究中,下一代测序在一组进行性肌肉无力的埃及患者(n=23)的基因编码胶原 VI 的三个α链(COL6A1、COL6A2 或 COL6A3)中显示出潜在的变异。根据发病年龄和患者临床病程,将患者诊断为以下类型:12 例 UCMD、8 例 BM 和 3 例中间疾病形式。在纳入的受试者中报告了 14 种致病性变异,包括 5 种新的改变。它们包括 3 种错义突变、3 种移码突变和 6 种剪接突变,分别在 4、3 和 6 个家族中发现。此外,还在单个家族中检测到无义变异,在 3 个不同家族中检测到框内变异。记录了 9 个家族的隐性遗传和 8 个家族的显性遗传。根据 ACMG 指南,将变异分类为致病性(n=7)、可能致病性(n=4)或意义未明的变异(VUS)(n=3),具有显著的致病性潜力。据我们所知,该研究首次报道了胶原 VI 缺乏症埃及患者的临床和遗传发现。研究队列中存在明显的家族内和家族间临床变异性。